Potential for patients with pancreatic cancer and leukemias
ONC212 is a nanomolar agonist of the orphan GPCR tumor suppressor GPR132, as well as ClpP. Similar to the downstream effects of ONC201 and ONC206, ONC212 activates the integrated stress response, inhibits Ras signaling and selectively kills tumor cells. ONC212 has broad-spectrum preclinical activity across both solid tumors and hematological malignancies, including pancreatic cancer and leukemias prioritized as target clinical indications that exhibit high GPR132 and/or ClpP expression.
A $3.4 million grant awarded to Brown University supports completion of IND-enabling studies and a first-in-human clinical trial.
ONC212 has broad-spectrum preclinical activity across both solid tumors and hematological malignancies